IL72117A0 - Improvements in or relating to immunotoxin conjugates - Google Patents

Improvements in or relating to immunotoxin conjugates

Info

Publication number
IL72117A0
IL72117A0 IL72117A IL7211784A IL72117A0 IL 72117 A0 IL72117 A0 IL 72117A0 IL 72117 A IL72117 A IL 72117A IL 7211784 A IL7211784 A IL 7211784A IL 72117 A0 IL72117 A0 IL 72117A0
Authority
IL
Israel
Prior art keywords
relating
immunotoxin conjugates
present
immunotoxin
conjugates
Prior art date
Application number
IL72117A
Other languages
English (en)
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of IL72117A0 publication Critical patent/IL72117A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40—High-molecular-weight compounds
    • C08G18/54—Polycondensates of aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/819—Multifunctional antigen or antibody
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL72117A 1983-06-21 1984-06-15 Improvements in or relating to immunotoxin conjugates IL72117A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/506,540 US4664911A (en) 1983-06-21 1983-06-21 Immunotoxin conjugates employing toxin B chain moieties

Publications (1)

Publication Number Publication Date
IL72117A0 true IL72117A0 (en) 1984-10-31

Family

ID=24015007

Family Applications (1)

Application Number Title Priority Date Filing Date
IL72117A IL72117A0 (en) 1983-06-21 1984-06-15 Improvements in or relating to immunotoxin conjugates

Country Status (18)

Country Link
US (1) US4664911A (de)
EP (1) EP0129434B1 (de)
JP (1) JPH0639387B2 (de)
KR (1) KR860001803B1 (de)
AT (1) ATE46084T1 (de)
AU (1) AU570049B2 (de)
CA (1) CA1232838A (de)
DE (1) DE3479633D1 (de)
DK (1) DK297184A (de)
ES (2) ES8604425A1 (de)
FI (1) FI842420A7 (de)
GB (1) GB2142032B (de)
GR (1) GR82368B (de)
HU (1) HUT34348A (de)
IL (1) IL72117A0 (de)
PL (1) PL248202A1 (de)
PT (1) PT78752A (de)
ZA (1) ZA844512B (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925922A (en) * 1983-02-22 1990-05-15 Xoma Corporation Potentiation of cytotoxic conjugates
FR2550944B1 (fr) * 1983-08-23 1985-12-06 Sanofi Sa Association pharmaceutique a base d'anticorps anticellules tumorales et de conjugues cytotoxiques, appropriee notamment pour le traitement des cancers
EP0232447A1 (de) * 1986-02-13 1987-08-19 Xoma Corporation Lektin-Immunotoxine
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US6103243A (en) * 1985-05-15 2000-08-15 Biotechnology Australia Pty, Ltd Oral vaccines
US5283323A (en) * 1985-08-07 1994-02-01 The United States Of America As Represented By The Department Of Health And Human Services Method of producing immune response
DE3688137D1 (de) * 1985-11-29 1993-04-29 Consolidated Pharmaceuticals L Ricin-antikoerper-konjugate.
FR2602682B1 (fr) * 1986-08-12 1988-12-02 Sanofi Sa Immunotoxines a longue duree d'action in vivo comportant une glycoproteine inhibant les ribosomes, modifiee par oxydation des motifs osidiques et formation d'une base de schiff
US4911911A (en) * 1985-12-20 1990-03-27 Sanofi Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged action immunotoxins containing such a glycoprotein
US4831122A (en) * 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
DE3751543T2 (de) * 1986-03-20 1996-04-11 Dana Farber Cancer Inst Inc Lektinkomplex, sowie verfahren und sonde zu dessen herstellung.
US5395924A (en) * 1986-03-20 1995-03-07 Dana-Farber Cancer Institute, Inc. Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity
US5239062A (en) * 1986-03-20 1993-08-24 Dana-Farber Cancer Institute, Inc. Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity
US4806494A (en) * 1986-07-24 1989-02-21 The United States Of America As Represented By The Department Of Health & Human Services Monoclonal antibody against ovarian cancer cells (OVB-3)
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
CA1340312C (en) * 1986-10-09 1999-01-12 Paul G. Abrams Methods for improved targeting of antibody, antibody fragments, hormonesand other targeting agents and conjugates thereof
US4808705A (en) * 1986-12-19 1989-02-28 Cetus Corporation Stable formulations of ricin toxin a chain and of RTA-immunoconjugates and stabilizer screening methods therefor
US4962048A (en) * 1987-02-19 1990-10-09 Scripps Clinic & Research Foundation Monoclonal antibodies to human pancreatic cancer
US5320942A (en) * 1987-02-19 1994-06-14 Vito Quaranta Method of diagnosing the presence of abnormal epithelial tissue using monoclonal antibodies to the A6 B4 cell surface protein
US5981278A (en) * 1987-05-29 1999-11-09 Tanox, Inc. Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS
US5834599A (en) * 1987-05-29 1998-11-10 Tanox Biosystems, Inc. Immunoconjugates which neutralize HIV-1 infection
US6657050B1 (en) 1987-05-29 2003-12-02 Tanox, Inc. Chimeric viral-neutralizing immunoglobulins
CA1335227C (en) * 1987-06-22 1995-04-11 Wylie W. Vale, Jr. Crf analog conjugates
IE890206L (en) * 1988-02-02 1989-08-02 Akzo Nv Immunotoxins from barley toxin
WO1989006967A1 (en) * 1988-02-03 1989-08-10 Xoma Corporation Immunosupression with anti-pan t-cell immunotoxin compositions
US5827934A (en) * 1988-03-08 1998-10-27 The University Of Wyoming Cytotoxic diphtheria toxin fragments
JPH02503867A (ja) * 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
US5149782A (en) * 1988-08-19 1992-09-22 Tanox Biosystems, Inc. Molecular conjugates containing cell membrane-blending agents
US5045451A (en) * 1988-10-26 1991-09-03 Board Of Regents Methods for screening antibodies for use as immunotoxins
US5621078A (en) * 1989-03-22 1997-04-15 Merck & Co., Inc. Modified pseudomonas exotoxin PE40
US6207798B1 (en) 1989-08-03 2001-03-27 Merck & Co., Inc. Modified PE40 toxin fusion proteins
CA2065029A1 (en) * 1989-09-14 1991-03-15 Ellen S. Vitetta Therapeutic compositions; methods for treatment of hiv infections
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5401243A (en) * 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
WO1992007574A1 (en) * 1990-10-25 1992-05-14 Tanox Biosystems, Inc. Glycoproteins associated with membrane-bound immunoglobulins as antibody targets on b cells
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
DE69219913T2 (de) * 1991-01-15 1997-09-11 Bayer Ag Ergänzung von Oberflächenrezeptoren
US7070991B2 (en) 1991-02-08 2006-07-04 Progenics Pharmaceuticals, Inc. Cells expressing a CD4-IgG2 chimeric heterotetramer
EP1340769B1 (de) 1991-02-08 2005-02-09 Progenics Pharmaceuticals, Inc. CD4-gamma2- und CD4-IgG2-Chimären
US5112607A (en) * 1991-06-05 1992-05-12 The United States Of America As Represented By The Secretary Of The Army Potentiation of immunotoxin action by Brefeldin A
WO1993004191A1 (en) * 1991-08-15 1993-03-04 Neorx Corporation Noncytolytic toxin conjugates
WO1993015113A1 (en) * 1992-01-24 1993-08-05 Tanox Biosystems, Inc. An immunotoxin including a cytotoxin with an unpaired cysteine residue in or near its receptor-binding site
US5686072A (en) * 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
WO1994007138A1 (en) 1992-09-14 1994-03-31 Fodstad Oystein Detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations
GB9305735D0 (en) * 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
ES2329232T3 (es) 1993-06-10 2009-11-24 Allergan, Inc. Tratamiento de trastornos y afecciones neuromusculares con un serotipo botulinico diferente.
US5876438A (en) * 1993-08-02 1999-03-02 Houston Biotechnology Incorporated Polymeric device for the delivery of immunotoxins for the prevention of secondary cataract
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
ES2159624T3 (es) 1993-12-28 2001-10-16 Allergan Sales Inc Toxinas botulinicas para el tratamiento de la hiperhidrosis.
US5759546A (en) 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
NO180658C (no) 1994-03-10 1997-05-21 Oeystein Fodstad Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5830478A (en) * 1995-06-07 1998-11-03 Boston Biomedical Research Institute Method for delivering functional domains of diphtheria toxin to a cellular target
US6497881B1 (en) * 1995-11-30 2002-12-24 New York University High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
US6960652B2 (en) * 1999-03-30 2005-11-01 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinaceous compounds
GB9909796D0 (en) * 1999-04-28 1999-06-23 Plant Bioscience Ltd Pesticidal fumes
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US7838007B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6500436B2 (en) 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US20040242523A1 (en) * 2003-03-06 2004-12-02 Ana-Farber Cancer Institue And The Univiersity Of Chicago Chemo-inducible cancer gene therapy
US8034791B2 (en) 2001-04-06 2011-10-11 The University Of Chicago Activation of Egr-1 promoter by DNA damaging chemotherapeutics
US20030082685A1 (en) * 2001-04-06 2003-05-01 WEICHSELBAUM Ralph R. Chemotherapeutic induction of egr-1 promoter activity
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
US20030211470A1 (en) * 2002-03-15 2003-11-13 Olson William C. CD4-IgG2-based salvage therapy of HIV-1 infection
US20050142139A1 (en) * 2003-03-21 2005-06-30 Norbert Schulke CD4-IgG2 formulations
CA2543566A1 (en) * 2003-11-14 2005-06-09 Jay W. Chaplin B-cell-targeted toxin for immuno response reduction
US7358334B1 (en) 2003-11-14 2008-04-15 Jay W Chaplin B cell-targeted toxins for humoral immune response reduction and methods of use thereof
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
ES2503719T3 (es) * 2005-02-11 2014-10-07 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
EP1863524A1 (de) * 2005-03-03 2007-12-12 Universite Catholique De Louvain Verfahren und zusammensetzungen zur behandlung von krebs
WO2006110623A2 (en) * 2005-04-09 2006-10-19 University Of Florida Research Foundation, Inc. Targeted cholera toxin for treatment of persistent or chonic pain
AU2006283726C1 (en) 2005-08-24 2015-05-07 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
WO2007109733A2 (en) 2006-03-21 2007-09-27 The Johns Hopkins University Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
CA2703364A1 (en) * 2007-10-23 2009-04-30 Allergan, Inc. Methods of treating chronic neurogenic inflammation using modified clostridial toxins
JP5805538B2 (ja) 2008-11-07 2015-11-04 リサーチ ディベロップメント ファウンデーション Ｃｒｉｐｔｏ／ＧＳＰ７８複合体形成およびシグナル伝達を阻害するための組成物および方法
MX2011012794A (es) 2009-06-03 2012-05-08 Immunogen Inc Metodos de conjugacion.
ME03353B (de) 2011-03-29 2019-10-20 Immunogen Inc Herstellung von maytansinoid-antikörperkonjugaten anhand eines einstufigen verfahrens
WO2014055877A1 (en) 2012-10-04 2014-04-10 Immunogen, Inc. Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
JPS55136235A (en) * 1979-04-09 1980-10-23 Teijin Ltd Antitumor protein complex and its preparation
JPS5616417A (en) * 1979-07-19 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation
JPS5616418A (en) * 1979-07-20 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation
JPS5686121A (en) * 1979-12-14 1981-07-13 Teijin Ltd Antitumor proten complex and its preparation
US4322495A (en) * 1980-03-11 1982-03-30 Minnesota Mining And Manufacturing Co. Immunoassay
EP0044167A3 (de) * 1980-07-14 1982-04-21 The Regents Of The University Of California Durch einen Antikörper gerichtetes zytotoxisches Mittel
US4359457A (en) * 1980-09-30 1982-11-16 Neville Jr David M Anti Thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant
US4440747A (en) * 1980-09-30 1984-04-03 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibody-ricin hybrids as a treatment of murine graft-versus-host disease
JPS5764617A (en) * 1980-10-08 1982-04-19 Teijin Ltd Cytotoxic proteinic complex and its preparation
US4397843A (en) * 1980-10-23 1983-08-09 The United States Of America As Represented By The Department Of Health And Human Services Mannose-6-phosphate-low density protein reagent effective against hypercholesterolemia
US4356117A (en) * 1980-10-23 1982-10-26 U.S. Govt., Dept. Of Health & Human Services Chemical modifications of proteins which induce new receptor specificities and therefore elicit new effects in cells
JPS57106625A (en) * 1980-12-22 1982-07-02 Teijin Ltd Cytotoxic protein complex and its preparation
JPS57106626A (en) * 1980-12-22 1982-07-02 Teijin Ltd Cytotoxic protein complex and its preparation
FR2498192A2 (fr) * 1981-01-22 1982-07-23 Pasteur Institut Nouveau compose polypeptidique thiole provenant d'un fragment de la toxine tetanique, son procede d'obtention et ses applications
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
JPS5874614A (ja) * 1981-10-30 1983-05-06 Teijin Ltd 蛋白複合体及びその製造法
FR2516794B1 (fr) * 1981-11-20 1985-10-25 Sanofi Sa Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique
FR2536997B1 (fr) * 1982-03-11 1987-08-07 Sanofi Sa Medicaments cytotoxiques comportant au moins une immunotoxine et de la methylamine
FR2523445A1 (fr) * 1982-03-17 1983-09-23 Sanofi Sa Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
US4500637A (en) * 1982-07-19 1985-02-19 The United States Of America As Represented By The Department Of Health And Human Services Prevention of graft versus host disease following bone marrow transplantation

Also Published As

Publication number Publication date
FI842420A0 (fi) 1984-06-14
ATE46084T1 (de) 1989-09-15
HUT34348A (en) 1985-03-28
ES533510A0 (es) 1986-02-01
ZA844512B (en) 1986-02-26
EP0129434B1 (de) 1989-09-06
AU570049B2 (en) 1988-03-03
DK297184D0 (da) 1984-06-18
FI842420L (fi) 1984-12-22
EP0129434A3 (en) 1985-09-18
DE3479633D1 (en) 1989-10-12
ES8606884A1 (es) 1986-04-16
US4664911A (en) 1987-05-12
JPH0639387B2 (ja) 1994-05-25
ES8604425A1 (es) 1986-02-01
KR850000248A (ko) 1985-02-26
EP0129434A2 (de) 1984-12-27
JPS6069033A (ja) 1985-04-19
GR82368B (de) 1984-12-13
GB8415507D0 (en) 1984-07-25
ES544846A0 (es) 1986-04-16
GB2142032B (en) 1987-05-13
PL248202A1 (en) 1985-03-26
KR860001803B1 (ko) 1986-10-23
GB2142032A (en) 1985-01-09
CA1232838A (en) 1988-02-16
AU2948084A (en) 1985-01-03
FI842420A7 (fi) 1984-12-22
DK297184A (da) 1984-12-22
PT78752A (en) 1984-07-01

Similar Documents

Publication Publication Date Title
IL72117A0 (en) Improvements in or relating to immunotoxin conjugates
MY108519A (en) Novel antibodies reactive with human carcinomas.
IL71366A0 (en) Immunoglobulin conjugates,their production and pharmaceutical compositions containing them
DE69637957D1 (de) Zusammensetzung für düngemitteladditivconzentrat
NZ229700A (en) Tetraazacyclododecane derivatives containing a linker/spacer moiety capable of forming antibody conjugates; complexes with radionuclides and conjugates of such compounds and complexes with antibodies or antibody fragments
IL99363A0 (en) Pharmaceutical compositions comprising homoconjugated monoclonal antibodies
IL103510A0 (en) Pharmaceutical compositions containing antibodies for causing immunosuppression
EP0504327A4 (en) Therapeutic uses of the hypervariable region of monoclonal antibody m195 and constructs thereof
AU561660B2 (en) Conjugate of ricin chain a and monoclonal antibody
IL109720A (en) N-alkylthio polyamine derivatives and radioprotective compositions containing them
IL97776A0 (en) Antibody conjugates for treatment of neoplastic diseases
NZ196775A (en) Allergen-polysarcosine conjugates and pharmaceutical compositions
FI915804A7 (fi) Kuituihin perustuva, flavoria vapauttava lisäaine savukekoostumuksia varten
MIYAZAKI et al. Preparation of antibody (IgG)-ricin A-chain conjugate and its biologic activity
EP0494247A4 (de)
NO943847L (no) Fremgangsmåte for fremstilling av makrocykliske chelateringsmidler og dannelse av chelater og konjugater derav
TW329425B (en) Immunoconjugates useful for treating gastro-intestinal tumors, processes for their preparation and pharmaceutical compositions containing them